<?xml version="1.0" encoding="UTF-8"?>
<Label drug="erygel" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">      ADVERSE REACTIONS  

  In controlled clinical trials, the incidence of burning associated with erythromycin topical gel USP, 2% was approximately 25%. The following additional local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness. Irritation of the eyes and tenderness of the skin have also been reported with the topical use of erythromycin. A generalized urticarial reaction, possibly related to the use of erythromycin, which required systemic steroid therapy has been reported.
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
